Focused on Partnerships

We are applying our drug developing expertise to design novel anti-cancer medicines that address serious unmet medical needs in oncology and autoimmune disease. Our team of experts is capable of creating mAbs, multi-specific antibodies and ADCs against targets of interest and providing phase I-ready assets to partners.

Our three unique assets targeting oxMIF, the key to drugging MIF:
  • ON203: OncoOne’s optimized therapeutic mAb targeting oxMIF in solid tumors
  • ON104: OncoOne’s oxMIF mAb specifically formulated for autoimmune disorders and severe inflammatory conditions
  • ON102: a diagnostic radioimmunoconjugate targeting oxMIF for the detection of malignant solid tumors and metastases
  • ON-05: the first asset from OncoOne’s proprietary PreTarg-it™ platform combining the tumor aggregation of oxMIF and radiotherapy in a powerful, yet highly targeted radioimmunoconjugate therapy

OncoOne is actively seeking partnerships, collaborations, and Series B investors in 2022 to accelerate the progression of our oxMIF candidates to the clinic

To discuss partnering or collaboration opportunities, please contact OncoOne’s Chief Business Officer, Brent Meadows.

We value our cooperation with excellent public grantpartners
and are proud to partner with top-tier academic collaborators.

Public Grants.

Austria Wirtschaftsservice GmbH

Austrian Federal Development and Financing Bank

Bundesministerium für Digitalisierung und Wirtschaftsstandort

Federal Ministry of Austria Digital and Economic Affairs

Bundesministerium für Verkehr, Innovation und Technologie

Federal Ministry of Austria Transport, Innovation and Technology

Österreichische Forschungsförderungsgesellschaft mbH

The Austrian Research Promotion Agency

Österreichische Forschungsförderungsgesellschaft mbH

The Austrian Research Promotion Agency


GenScript PROBIO

Imperial College London

Adgyl Life Sciences

University of Catania

Medizinische Universität Graz

Head offices
in Boston (USA) and Vienna (Austria)

Cooperation partners
from China, France, Germany, India, Italy, Netherlands, Northern Ireland, Switzerland, UK, US